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Abstract
Selenium protects cells and inhibits many inflammatory cell
mechanisms through antioxidant seleno-enzymes. Immunity improve-
ment is illustrated by the study of Berger and colleagues, with
reduction of nosocomial pneumonia in burnt patients under multi-
trace-element supplementation. As seleno-compounds (especially
sodium selenite) are pro-oxidant, however, administration above
800 µg/day may be dangerous in septic shock. Paradoxically,
direct reversible pro-oxidative effects of seleno-compounds may
also be beneficial for reduction of inflammation (genomic action,
apoptosis), and may even be bactericidal or virucidal. These facts
need to be further examined, as well as the possible dramatic drop
of plasma selenoprotein P in septic shock and its role in endo-
thelium protection.
Biological and medical advances in the area of selenium
provide interest in selenium for both its antioxidant properties
through seleno-enzyme incorporation, as illustrated in the
previous issue of Critical Care [1], and its direct pro-oxidant
toxic effect through seleno-compounds.
In intensive care, and especially in septic shock adjunctive
therapy, there is a growing interest in the antioxidant role of
selenium [2-5]. We know that there is a very low level of
selenium in the human (20 mg for the whole body) but that a
severe deficiency is lethal [6]. We also know that selenium
plays a crucial role in antioxidant defense, as one selenium
atom is absolutely required at the active site of all seleno-
enzymes in the form of the 21-amino-acid selenocystein [6,7].
Mammals largely use seleno-enzymes for antioxidant
purposes, whereas bacteria do not. The seleno-enzymes are
ubiquitous in mammal cells and have two main roles. Firstly,
the seleno-enzymes protect cell components against
oxidation: membranes, enzymes, proteins, and DNA.
Secondly, seleno-enzymes inhibit proinflammatory cell
metabolisms by reducing the peroxide tone of intracellular
water (NF-κB, acid arachidonic and complement cascades,
and mitochondria) [6,8]. As a consequence, selenium has
been found to improve immunity [6,7]. In septic shock patients
there is a dramatic and early decrease of the plasma selenium
concentration [9].
In the previous issue of Critical Care, Berger and colleagues
[1] reported the results of a very interesting aggregative study
on a group of 41 severely burnt patients. The authors show a
significant reduction of nosocomial pneumonia by intravenous
multitrace-element supplements (copper, selenium, and zinc).
These results confirm Berger’s research on burnt and trauma
patients conducted since 1986 [4]. This particular population
has lower mortality than septic shock patients [2].
The approach of these studies is to increase the antioxidant
defense by supplementing patients with multimicro-nutrients
(vitamins and trace elements) when there is a dangerous
overproduction of free radicals [4]. In these studies Berger
progressively focused on selenium, and increased the
amount of selenium supplementation. Berger and colleagues,
however, continue to use doses of selenium lower than 1 mg.
For convenience sake, these studies used the easily available
pro-oxidative sodium selenite compound, as have most – if
not all – other studies in intensive care unit patients. But the
question of the compound probably has little importance
when administrated at a level close to the nutritional
800 µg/day no-observed-adverse-effect level for selenium [7].
The two meta-analyses [2,3] tend to conclude that there is a
mortality decrease in septic shock patients when selenium is
administrated at higher doses, but is still less than 1 mg.
There may be another explanation for the efficiency of such
high 1 mg selenium doses, especially when administered
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early. In plasma, selenoprotein P – the main form of plasma
selenium – seems to rapidly and dramatically decrease in
septic shock patients [10]. This protein has been described
to protect the endothelium against oxidative stress related to
peroxynitrite in a rat model of diquat intoxication, which may
also be the case in septic shock [10-12]. In fact, the liver
incorporates selenium and may induce a rapid synthesis of
selenoprotein P.
Even though it seems that higher doses of sodium selenite
supplementation are more effective in sepsis, we must
remember that sodium selenite is a pro-oxidant compound.
We must therefore be prudent in administrating sodium
selenite, especially intravenously, in oxidative stress related to
septic shock or similar syndromes, when there is additional
risk of drug interactions [13,14]. In fact, all seleno-
compounds are known to be more or less pro-oxidant
compounds as selenium belongs to the same column of the
periodic table as oxygen [13,15,16]. Acute selenium
intoxication leading to shock and acute respiratory distress
syndromes may be lethal, similar to arsenic poisoning [17].
Paradoxically, the direct pro-oxidative effect of selenium
compounds may be beneficial in septic shock treatment. As
previously stated [10], selenium compounds – especially
sodium selenite – may have a direct inhibition of NF-κB to
DNA binding through a reversible rupture of the disulfide
bridge fixation. Selenium compounds may similarly inhibit
cellular adhesion and even, at higher concentration, induce a
reversible proapoptotic effect, which may help reduce
overactivated phagocytic cells [16]. At even higher
concentrations, seleno-compounds may be bactericidal or
virucidal [15].
Unpublished animal studies support such an interest in
cautious use of very high doses of selenium in sepsis [18]. In
addition, we can note that the studies on septic shock with
the most positive results used a sodium selenite first injection
as a bolus, resulting in a transient peak of blood selenite
concentration [19,20]. The pro-oxidant effect is most probably
transitory due to the rapid incorporation of selenium into the
seleno-enzymes, causing an antioxidant action. At least five
ongoing randomized monocenter or multicenter studies have
differing results, including our sérenité study. These studies
will certainly help us understand the role of dosage and the
method of administration.
Selenoprotein P and selenium compounds, especially sodium
selenite, should therefore be further examined for their
potential interests in the diagnosis and treatment of septic
shock and related syndromes.
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